Intra-Cellular Therapies Inc (ITCI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sharon Mates
Employees:
73
430 EAST 29TH STREET, NEW YORK, NY 10016
212-923-3344

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. Intra-Cellular Therapies was founded by Paul Greengard on August 29, 2013 and is headquartered in New York, NY.

Data derived from most recent annual or quarterly report
Market Cap 5.496 Billion Shares Outstanding93.594 Million Avg 30-day Volume 993.419 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.5
Price to Revenue56.079 Debt to Equity0.0 EBITDA-311.627 Million
Price to Book Value7.2806 Operating Margin-296.4712 Enterprise Value4.998 Billion
Current Ratio14.361 EPS Growth-0.152 Quick Ratio13.622
1 Yr BETA 0.8598 52-week High/Low 66.0 / 28.4 Profit Margin-294.8909
Operating Cash Flow Growth-30.0123 Altman Z-Score43.6332 Free Cash Flow to Firm -234.309 Million
Earnings Report2022-08-08
View SEC Filings from ITCI instead.

View recent insider trading info

Funds Holding ITCI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ITCI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

96.3 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

86.3 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SALAS EDUARDO RENE

  • Director
0 2022-04-20 2

NEUMANN MARK EVP, CHIEF COMMERCIAL OFFICER

  • Officer
45,339 2022-04-08 6

RIGGS RORY B

  • Director
77,072 2022-03-31 6

VAN NOSTRAND ROBERT L

  • Director
8,935 2022-03-31 5

HALSTEAD MICHAEL EVP AND GENERAL COUNSEL

  • Officer
39,950 2022-03-10 5

HINELINE LAWRENCE J. SVP OF FINANCE CFO

  • Officer
30,362 2022-03-10 5

MATES SHARON CHAIRMAN, PRESIDENT & CEO

  • Officer
  • Director
111,863 2022-03-10 7

DURGAM SURESH K. CHIEF MEDICAL OFFICER

  • Officer
39,950 2022-03-10 6

MARCUS JOEL S

  • Director
113,643 2022-03-07 3

LERNER RICHARD A

  • Director
108,093 2021-09-30 3

RAWLINS MICHAEL

  • Director
0 2021-06-21 2

ALAFI CHRISTOPHER D

  • Director
5,689,318 2021-05-27 0

SATLIN ANDREW EVP AND CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-18 0

DAVIS ROBERT E SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
43,989 2019-01-04 0

VANOVER KIMBERLY E. SVP, EARLY STAGE CLINICAL DEV.

  • Officer
27,068 2019-01-04 0

ALAFI MOSHE

  • 10% Owner
3,953,270 2017-10-02 0

ALAFI CAPITAL CO LLC

  • 10% Owner
3,953,270 2017-10-02 0

FIENBERG ALLEN A. VP OF BUSINESS DEVELOPMENT

  • Officer
492,823 2015-08-19 0

WENNOGLE LAWRENCE P. VICE PRESIDENT, DRUG DISCOVERY

  • Officer
126,500 2015-06-08 0

SANCHEZ JUAN F. VP, CORP. COMMUNICATIONS & IR

  • Officer
0 2015-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MARCUS JOEL S - Director

2022-05-13 17:24:37 -0400 2022-05-12 S 10,000 $55.00 d 54,233 direct 0.8316 -0.8656 0.8316 2 -2.0197 4

SALAS EDUARDO RENE - Director

2022-04-21 16:54:37 -0400 2022-04-20 A 20,000 a 20,000 direct

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2022-04-08 18:56:51 -0400 2022-04-08 S 17,476 $63.55 d 114,211 direct yes 0.9082 -2.645 -9.2416 3.0911 3 -31.485 20

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2022-04-08 18:56:51 -0400 2022-04-08 M 86,348 d 0 direct

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2022-04-08 18:56:51 -0400 2022-04-08 S 14,885 $65.14 d 45,339 direct yes 0.9082 -2.645 -9.2416 3.0911 3 -31.485 20

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2022-04-08 18:56:51 -0400 2022-04-08 M 86,348 $12.73 a 131,687 direct 0.9082 -2.645 -9.2416 3.0911 3 -31.485 20

NEUMANN MARK - Officer EVP, CHIEF COMMERCIAL OFFICER

2022-04-08 18:56:51 -0400 2022-04-08 S 53,987 $64.42 d 60,224 direct yes 0.9082 -2.645 -9.2416 3.0911 3 -31.485 20

VAN NOSTRAND ROBERT L - Director

2022-04-04 16:11:01 -0400 2022-03-31 A 126 $61.19 a 8,935 direct 3.8443 0.1898 -7.4514 3.8443 2 -31.9728 24

RIGGS RORY B - Director

2022-04-04 16:08:02 -0400 2022-03-31 A 257 $61.19 a 77,072 direct 3.8443 0.1898 -7.4514 3.8443 2 -31.9728 24

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-27 13:45:03 UTC 0.2185 0.6015 2400000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-27 13:15:03 UTC 0.2185 0.6015 2400000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-27 12:45:03 UTC 0.2185 0.6015 2200000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 22:15:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 21:45:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 21:15:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 20:45:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 20:15:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 19:45:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 19:15:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 18:45:04 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 18:15:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 17:45:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 17:15:03 UTC 0.2185 0.6015 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 16:45:04 UTC 0.2837 0.5363 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 16:15:03 UTC 0.2837 0.5363 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 15:45:03 UTC 0.2837 0.5363 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 15:15:03 UTC 0.2837 0.5363 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 14:45:03 UTC 0.2796 0.5404 2300000
INTRA-CELLULAR THERAPIES INC ITCI 2022-05-26 14:15:03 UTC 0.2796 0.5404 2300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund ITCI -20.0 shares, $-307.4 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund ITCI -95.0 shares, $-1460.15 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund ITCI -53.0 shares, $-814.61 2020-03-31 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity Fund ITCI -706.0 shares, $-28578.88 2021-11-30 N-PORT
VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND ITCI -37317.0 shares, $-1953171.78 2021-12-31 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity ETF ITCI -706.0 shares, $-39168.88 2022-02-28 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund ITCI -12173.0 shares, $-578095.77 2022-01-31 N-PORT
RUSSELL INVESTMENT CO- Sustainable Equity Fund ITCI -2047.0 shares, $-97212.03 2022-01-31 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund ITCI -770.0 shares, $-47116.3 2022-03-31 N-PORT
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund ITCI -2141.0 shares, $-131007.79 2022-03-31 N-PORT

Elevate your investments